A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."

"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."